|
  
- 积分
- 97
- 威望
- 97
- 包包
- 3142
|

本帖最后由 bobo 于 2009-6-28 08:34 编辑 . G4 t% F. ]3 I( d) n
; K8 f* S6 O* P% t
表观遗传学与干细胞——2009年亚洲生物高峰论坛录制(音频mp3)& R$ j7 }' U* K: b0 ~
v2 e5 p) C! g$ d* \0 r7 \
/ Q$ ~ ]5 W, T
- e9 ^8 X1 k, B. m/ d回复为ppt
) L! Z8 p) D$ U, k' n$ k' D9 D( s3 ^摘要:
4 n0 T8 l- S9 s& m+ W$ O5 L4 Z+ P) n5 u( ]; o* u l. i
Hongkui Deng
( I+ m# X/ w7 w& }" h; Y( n7 ?
7 N! c. ?/ |' ^2 K; zLaboratory of Stem Cell and Generative Biology, College of Life Sciences, Peking University, Beijing 100871, China.
' ]/ l0 e1 G0 R) O. y9 c
+ m& B% n# x2 N; q7 z2 HHuman pluripotent stem cells represent a potentially unlimited source of functional pancreatic endocrine lineage cells. We established a new highly efficient approach to induce human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells to differentiate into mature insulin-producing cells in a chemical-defined culture system. The differentiated cells obtained by this approach comprised nearly 25% insulin-positive cells as assayed by flow cytometry analysis, which released insulin/C-peptide in response to glucose stimuli in a manner comparable to that of adult human islets. Most of these insulin-producing cells co-expressed mature beta cell-specific markers such as NKX6-1 and PDX1, indicating a similar gene expression pattern to adult islet beta cells in vivo. This work provides a new model to study the mechanism of human pancreatic specialization and maturation in vitro, and enhances the possibility of utilizing patient-specific iPS cells for the treatment of diabetes3 k0 F! i& A9 O: o
* H' R. h* p$ |6 J# R" f7 L
回复为ppt
/ D/ l$ \' E9 A+ D. Z8 z5 g; Y2 L4 e' F& y
8 V3 ~) d8 [ G
; g S9 p4 M3 l
) R6 u( B0 h/ A# y, W: w |
附件: 你需要登录才可以下载或查看附件。没有帐号?注册
|